Brain Awareness Week 2021: Tackling Motor Neurone Disease through research

Posted on: 17 March 2021

Within the Academic Unit of Neurology at Trinity, the main research focus is on Amyotrophic Lateral Sclerosis (ALS), also known as Motor Neurone Disease (MND).  ALS/MND is a fatal neurodegenerative disease that strikes in midlife and kills one person every 2 days in Ireland.    People with ALS experience rapidly progressive and ultimately fatal decline in their ability to  move their muscles, to speak and to swallow. Half of those affected by ALS experience decline in their ability to process information and to manage their behaviour.

Brain Awareness Week 2021: Tackling Motor Neurone Disease through research

There is now strong evidence that  ALS has many different causes, and that there are  considerable  differences in how the disease behaves.   Some people die within 2 months of their first symptom, and some can live for over 50 years (for example, Stephen Hawking). Some have thinking problems and others remain intact.  And research has found that some belong to families with a higher than expected number of members with additional neurological and psychiatric disorders, while others have no family members with any type of brain disorder.

Professor Orla Hardiman and her team’s world class research strengths are in clinical evaluation, epidemiology, neuropsychology,  genetics, brain imaging and neural engineering. They work closely with the  Trinity Clinical Research Facility, St James Hospital and atBeaumont Hospital in Dublin.   The team’s research will help to  fast track and  reduce the cost of clinical trials by making sure that the right drug is given to the right patient at the right time, in the right dose, using a precision medicine approach.   Precision medicine recognizes that the factors leading to disease are likely to differ  between patients, and that a much better understanding of basis for these differences is required.

Professor Orla Hardiman


To achieve this,  Professor Hardiman and her team are developing research tools that will allow them to reliably  identify distinct subgroups of patients  with well-defined characteristics.    Some of these characteristics can been identified by detailed clinical examination or neuropsychological assessment, or by genetic analysis.  But other characteristics will require new  innovations in brain wave mapping and imaging.





Recent research successes at the Academic Unit of Neurology

In the past year, the team have had some notable successes in their research.  They have  participated  in the first gene-based therapy trial for ALS and have two similar trials planned for this year (2021).

Their epidemiology research has shown that genetic factors contribute to half of the risk of developing ALS, and they are working with the International Project MinE Consortium ( , and colleagues in South America to identify which combinations of genes increase  or reduce the risk. Interestingly, they are also studying whether different ancestral populations have different manifestations of ALS.

EEG studies undertaken by the team have shown that different subgroups of patients have different and distinct patterns of brain network disruption. These patterns also predict how fast or slow the disease progresses, and these patterns are also reflected in changes in the brain that we can detect on MRI.

The work with those with the disease has been instructive in  teaching  the research team that how people experience illness  often  differs from how doctors define disease progression.  As a result, they are now developing  better measures that incorporate  with greater clarity the perspectives of those with the condition and their families.

Professor Hardiman’s team recognised the impact that the COVID pandemic was having on patients with MND and the difficulties it presented in terms of the provision of medical care and support. In response they have developed a new smart phone application that will allow them to develop new and better ways to monitor the disease and reduce the need for patients to attend the hospital.   You can read more about this exciting development here:

Media Contact:

Ciara O’Shea, Media Relations Officer | | +353 1 896 4337